Please assess the completion status of the following clinical trial:

Trial Title: Racial Differences in Vagal Control of Glucose Homeostasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* African American or white (race will be self-defined, but only subjects who report both parents of the same race will be included)~* 18-60 years old~* BMI 30-45 Kg/m2~* Not pregnant or breastfeeding~Exclusion Criteria:~* Pregnant or breastfeeding~* Diabetes diagnosis (defined by the American Diabetes Association (ADA) criteria)38~* Cardiovascular disease such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy.~* Arrhythmia (first-, second-, and third-degree atrioventricular (AV) block)~* Significant weight change \>5% in the past 3 months~* Impaired hepatic function (AST and/or Alanine transaminase (ALT) \> one and one half times (1.5X) upper limit of normal range)~* Impaired renal function (eGFR \<60ml/min)~* Users of strong inhibitors of Cytochrome P450 3A4 (CYP3A4) or cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6)~* Users of other acetylcholinesterase inhibitors such as pyridostigmine or bethanechol~* History of alcohol or drug abuse~* Mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study~* Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Galantamine 16 mg then placebo (Type: EXPERIMENTAL): Galantamine 16 mg po one time dose then placebo on 2nd visit
- Placebo then Galantamine 16 mg (Type: PLACEBO_COMPARATOR): Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit

Based on this trial design, predict the completion outcome and termination type (if applicable).